CELL AND GENE THERAPY

Enabling the Future of Cell & Gene Therapies through Non Proprietary Patient-Owned Data Collection

March 16, 2021

herapies through Non Proprietary
Cell and gene therapies have emerged as a new treatment paradigm, and with them has come the potential
to alter the course of many rare diseases. In many cases, there is an opportunity to correct the underlying
dysfunction with a one-time administration of a therapy and provide either a functional cure or a substantial
improvement in health outcomes. In other cases, long term symptom relief will be the primary therapeutic
objective. Some of these indications may require more than one dose to achieve continued symptom relief
and scientists and companies are working on technologies that will enable the use of a repeat dose.

Spotlight

ACEA Biosciences

The Life Technology Business Unit developed ACEA’s proprietary real-time, label-free cell-based assay technology and launched the first product in 2004. The technology ismarketed globally under the xCELLigence and NovoCyte brands.

OTHER WHITEPAPERS
news image

How advanced purification technologies are speeding the hunt for new protections against disease

whitePaper | November 24, 2022

Smallpox was the first infectious disease for which an effective vaccine was developed. In the late 1700s, British doctor Edward Jenner devised a method to inoculate people with cowpox pus to give them immunity against smallpox, a much more deadly disease.

Read More
news image

Document quality control emerges as a discipline in its own right

whitePaper | November 19, 2022

Compiling a quality regulatory submission is a basic requirement for biopharmaceutical companies. Poor quality documents could lead to rejection of a regulatory application,

Read More
news image

HIGH THROUGHPUT AAV VIRAL TITERING USING NANOPLATE-BASED DIGITAL PCR

whitePaper | December 22, 2022

Determining the physical titer of viral vectors has typically been accomplished using digital droplet PCR (ddPCR). Droplet-based methods, however, are challenged by matrix effects and long analysis times (up to 7 hours).

Read More
news image

Becoming a life sciences superpower

whitePaper | September 1, 2021

This report advocates for increased, long-term public investment in research and innovation, particularly in the life sciences sector, to accelerate the UK on its trajectory as a global leader in the field. This report sets out recommendations ahead of the Comprehensive Spending Review for policymakers to support innovative businesses, achieve the Prime Minister’s aim of becoming a life sciences superpower, and ultimately, deliver health benefits for Britain – and the world – for generations to come.

Read More
news image

Biocontamination control in pharmaceutical production

whitePaper | November 11, 2022

Biocontamination refers to biological contamination of products by bacteria and/or fungi, as well as the toxic by-products of these microorganisms, such as endotoxin and mycotoxins from Gram-negative bacteria and fungi, respectively.

Read More
news image

Multi-Attribute Methods for Biopharmaceutical Analysis

whitePaper | December 5, 2022

The adoption of LC-MS-based multi-attribute method (MAM) analysis for routine monitoring of biotherapeutic variation has progressed greatly over the last five years.

Read More

Spotlight

ACEA Biosciences

The Life Technology Business Unit developed ACEA’s proprietary real-time, label-free cell-based assay technology and launched the first product in 2004. The technology ismarketed globally under the xCELLigence and NovoCyte brands.

Events